Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer by Maurizio Capuozzo, Mariachiara Santorsola, Monica Ianniello, Francesco Ferrara, Andrea Zovi, Nadia Petrillo, Rosa Castiello, Maria Rosaria Fantuz, Alessandro Ottaiano, Giovanni Savarese

“…This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.…”
Get full text

Fully Supramolecular Polyrotaxanes as Biphase Drug Delivery Systems by Abdolhossien Massoudi, Mohsen Adeli, Leila Khosravi far

“…Fluorescein (Fl) as a model drug was conjugated to the hydroxyl functional groups of cyclodextrin rings of PPR via ester bonds and PPR-Fl as the primary drug delivery system was obtained. …”
Get full text

The Application of a Desktop NMR Spectrometer in Drug Analysis by Yonghong Zhong, Kejian Huang, Qiulian Luo, Suzhi Yao, Xiaofeng Liu, Ning Yang, Cuiwu Lin, Xuan Luo

“…A desktop NMR spectrometer was used to qualitatively analyze samples in drug-related cases in order to enhance the accuracy of the results and identify new drugs. …”
Get full text

HDN-DDI: a novel framework for predicting drug-drug interactions using hierarchical molecular graphs and enhanced dual-view representation learning by Jinchen Sun, Haoran Zheng

Subjects: “…Drug-drug interactions…”
Get full text

Mathematical rules for synergistic, additive, and antagonistic effects of multi-drug combinations and their application in research and development of combinatorial drugs and special medical food combinations by Shoujun Yuan, Haoyu Chen

“…Multi-drug (or multi-element) combinations are often prescribed in the practice of clinical medicine and as foods for special medical purposes. …”
Get full text

Scalable Manufacturing Method for Model Protein-Loaded PLGA Nanoparticles: Biocompatibility, Trafficking and Release Properties by Selin Akpinar Adscheid, Marta Rojas-Rodríguez, Salma M. Abdel-Hafez, Francesco S. Pavone, Marc Schneider, Akif E. Türeli, Martino Calamai, Nazende Günday-Türeli

Subjects: Get full text

A Challenge for Diagnosing Acute Liver Injury with Concomitant/Sequential Exposure to Multiple Drugs: Can Causality Assessment Scales Be Utilized to Identify the Offending Drug? by Roxanne Lim, Hassan Choudry, Kim Conner, Wikrom Karnsakul

“…Drug-induced hepatotoxicity most commonly manifests as an acute hepatitis syndrome and remains the leading cause of drug-induced death/mortality and the primary reason for withdrawal of drugs from the pharmaceutical market. …”
Get full text

Peptide hydrogel-drug conjugates for tailored disease treatmentGuidelines to assemble peptide-based hydrogel-drug conjugates, referenced with a selection of relevant publications. by Thibault Cauwenbergh, Steven Ballet, Charlotte Martin

Subjects: Get full text

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek

“…However, fear for increased anti-drug antibody (ADA) formation due to interval prolongation of biologics is an important barrier.Objective To investigate the course of serum drug concentrations, ADA levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis.Methods Patients were randomized to dose reduction (DR) or usual care (UC) and followed for one year. …”
Get full text

Deprescribing: An umbrella review by Japelj Nuša, Horvat Nejc, Knez Lea, Kos Mitja

Subjects: Get full text

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities by Nai Lee, Su‐jin Rhee, Seong Min Koo, So Won Kim, Gyo Eun Lee, Yoon A Yie, Yun Kim

Subjects: “…drug information…”
Get full text

Linking machine learning and biophysical structural features in drug discovery by Armin Ahmadi, Shivangi Gupta, Vineetha Menon, Jerome Baudry

Subjects: “…drug discovery…”
Get full text

Identifying Drug Prescription in Newly Diagnosed Hypertension Patients in India by Thomas Alexander, Jagdish S. Hiremath, Jitendra P. S. Swahney, Subhash Chandra, Peeyush Jain, Praveen Chandra, Nakul Sinha, T. Sashikanth, Yugandhar Bachhu, Anil Balachandran, Pathiyil Balagopalan Jayagopal, T. Govindan Unni, Tiny Nair, Kumaresan Kannan, Dorairaj Prabhakar, M. Chenniappan, Ajay U. Mahajan, Rajiv D. Karnik, Chandrashekhar K. Ponde, Prashant Advani, Idris Ahmed Khan, Brij Mohan Goyal, P. R. Vaidyanathan, Hiren Prajapati, Willem J. Verberk

“…ABSTRACT This study evaluated initial antihypertensive drug prescription patterns in Indian healthcare settings. …”
Get full text

A comprehensive review on roles of electrochemical approaches in drug delivery by Ali R. Jalalvand, Mohammad Mehdi Karami

Subjects: Get full text

Nanotechnology-Based Drug Delivery Systems, 2nd Edition by Andrey N. Kuskov, Ekaterina V. Kukovyakina

Get full text

Eccentric indices based QSPR evaluation of drugs for schizophrenia treatment by Muneeba Mansha, Sarfraz Ahmad, Zahid Raza

“…Creating computational tools to find and develop drugs for schizophrenia has more interest in the past few years. …”
Get full text

Development, opportunities, and challenges of siRNA nucleic acid drugs by Bowen Xiao, Shaopeng Wang, Yu Pan, Wenjun Zhi, Chensheng Gu, Tao Guo, Jiaqi Zhai, Chenxu Li, Yong Q. Chen, Rong Wang

Subjects: Get full text

Stapled peptides: targeting protein-protein interactions in drug development by Qian Zhang, Ziyang Wang, Xiaohan Mei, Quan Chen, Chunqiu Zhang

“…Exploration of Drug Science…”
Get full text

Real-World Experience with Dolutegravir-Based Two-Drug Regimens by Douglas Ward, Moti Ramgopal, David J. Riedel, Cindy Garris, Shelly Dhir, John Waller, Jenna Roberts, Katie Mycock, Alan Oglesby, Bonnie Collins, Megan Dominguez, James Pike, Joseph Mrus

“…Background. Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. …”
Get full text

Editorial: Drug repurposing for cancer treatment: current and future directions by Marios Lampros, Nikolaos Vlachos, Georgios D. Lianos, Christina Bali, George A. Alexiou

Get full text